Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

But Novartis stock climbed 1.4% to close at 112.26 as Travere stock fell 7.7%, closing at 16.56. Novartis Stock: A Long History Behind Atrasentan.

Novartis' free cash flow increased by an impressive 5.7% in 2024, reaching $13.8 billion against $13.1 billion a year earlier. FCF even exceeded its net profit ($11.9 billion).

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

A Novartis executive said “it’s too early to say” whether the company would submit an experimental myelofibrosis drug for approval this year, amid questions about the medicine’s data profile.

Novartis has also been examining Lutathera for other indications. In September, it released Phase 2 data on Lutathera improving progression-free survival in patients with meningioma brain tumors. The ...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease Provided by GlobeNewswire Jun 26, 2025, 10:30 ...